China will try two private investigators tied to GlaxoSmithKline's operations there in just over a week on charges of illegally purchasing personal information about Chinese nationals, a Chinese court said. And according to state news agency Xinhua, all are welcome to attend.
Johnson & Johnson's new blood cancer drug Imbruvica (ibrutinib) is on a roll. The FDA just armed the drug with a new indication in chronic lymphocytic leukemia, adding to a series of regulatory nods.
Let GlaxoSmithKline be clear: It's open to spinning off its consumer healthcare division at some nebulous point in the future. But it's not happening anytime soon.
Pfizer beat analyst expectations for earnings. That's not as positive as it sounds, and it's certainly not the whole story.
Merck surprised Wall Street analysts today when it announced that its net profit in the second quarter jumped to $2 billion from $906 million in the same period a year ago, and that it was raising the lower end of its income forecast for 2014. But it's not exactly time to pop out the champagne corks and declare a successful turnaround.
Drugmakers cheer when influential doctors' groups revise treatment guidelines to include new drugs. But as AstraZeneca's MedImmune unit knows, those groups can backpedal.
The job-cutting ax has come out for Merck's U.S. field force, as part of a move to cut 600 positions by August.
The chilly sales climate in China is just now warming up after last summer's wave of bribery accusations spooked doctors and sales reps. But as far as Merck KGaA is concerned, China is warm enough to deliver doubled revenues in the region. And that's exactly what the German drugmaker's shooting for.
The string of pharma M&A deals fueled by the lure of cutting taxes continues and Midwest-based Hospira is now said to be about to take the plunge. Its vehicle of choice is the medical nutrition business of France's Danone, which sources say it is negotiating to buy in a deal that could run to $5 billion.
Reckitt Benckiser has been dropping plenty of hints that it would eventually spin off its pharmaceuticals unit. The time is here: The company says it will break off its pharma unit via with a separate U.K. listing, becoming the latest drugmaker to join pharma's slim-down craze.
Last week, France made its move to knock the Novartis eye drug Lucentis out of drug coverage and move its cheaper cousin Avastin into its place. Now, Novartis and its Lucentis partner Roche are fighting back.
GlaxoSmithKline pulled off a $20 billion asset swap with Novartis in April, hiving off its oncology business and building up in consumer health and vaccines in one fell swoop. But that restructuring might not be enough, CEO Andrew Witty tells the Financial Times. A future spin-off may be in order.
Merck is going through a complete makeover, buying and selling units at a rapid pace. And some of its employees are getting caught in its "out with the old and in with the new" philosophy. Now 600 sales reps have been told their services are no longer needed
It remains to be seen whether unconventional M&A tactics from Valeant's takeover partner, Bill Ackman, will help the pair get a deal for Allergan done. But in the meanwhile, one lawmaker is putting heat on the SEC to consider revising the rules that allowed them.
Nexavar, the blockbuster cancer drug sold by Bayer and Onyx Pharmaceuticals, has failed again in a trial for a new indication.
A Johnson & Johnson exercise in creative problem solving has paid off for doctors and patients who rely on its ovarian cancer drug Doxil, availability of which has been uncertain for years. Its Janssen unit has accumulated a significant supply after assuming manufacturing at Boehringer Ingelheim plant that otherwise was closed down at the end of the year.
Gilead Sciences, which this week got FDA approval for its new blood cancer drug Zydelig (idelalisib), has now gotten a recommendation for its use in Europe. But competitor Imbruvica from Johnson & Johnson, which got a head start in the U.S., also received a nod from EU authorities today.
AbbVie may have just struck a deal with Shire in order to diversify beyond its top drug, Humira. But that doesn't mean the drug isn't steamrolling.
The British company said Thursday that it had received an email containing allegations from a whistleblower pertaining to bribes paid by GSK's consumer healthcare operation in Syria before it was shut down amidst the country's civil war in 2012.
Bristol-Myers Squibb's melanoma drug Yervoy and clot-fighter Eliquis helped boost its earnings past analyst forecasts, with $333 million in profits on $3.9 billion in revenue.